Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer
Status:
Completed
Trial end date:
2017-01-23
Target enrollment:
Participant gender:
Summary
A first in human experimental treatment in which an experimental medicine,Nuc-1031, is used
in combination with a standard cancer medicine, carboplatin, to treat ovarian cancer which
reappear after standard cancer treatment. The aim of the trial is to determine safety,
effectiveness, and clinical activity of this combination treatment.